Benzinga | Mar 11, 2021 06:30AM EST

Oppenheimer Upgrades Catabasis Pharmaceuticals to Outperform, Announces $5 Price Target

Oppenheimer analyst Hartaj Singh upgrades Catabasis Pharmaceuticals (NASDAQ:CATB) from Perform to Outperform and announces $5 price target.